Azaquinazoline pan-KRas inhibitors
US-2023072276-A1 · Mar 9, 2023 · US
Tetrahydropyridopyrimidine pan-KRas inhibitors
US11999753B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11999753-B2 |
| Application number | US-202117553224-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 16, 2021 |
| Priority date | Dec 16, 2020 |
| Publication date | Jun 4, 2024 |
| Grant date | Jun 4, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to compounds that inhibit at least one of KRas wild type, KRas G12A, KRas G12C, KRas G12D, KRas G12R, KRas G12S, KRas G12V, KRas G13D and KRas Q61H, pharmaceutical compositions comprising the compounds and methods of use therefor.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound selected from: and a pharmaceutically acceptable salt thereof. 2. The compound of claim 1 , wherein the compound is or a pharmaceutically acceptable salt thereof. 3. The compound of claim 1 , wherein the compound is or a pharmaceutically acceptable salt thereof. 4. The compound of claim 1 , wherein the compound is or a pharmaceutically acceptable salt thereof. 5. A pharmaceutical composition comprising a therapeutically effective amount of a compound of any one of claim 1 , 3 , 4 , or 2 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
Assignees
Inventors
Classifications
- C07D519/00Primary
Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 · CPC title
Antineoplastic agents · CPC title
Ortho-condensed systems · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11999753B2 cover?
- The present invention relates to compounds that inhibit at least one of KRas wild type, KRas G12A, KRas G12C, KRas G12D, KRas G12R, KRas G12S, KRas G12V, KRas G13D and KRas Q61H, pharmaceutical compositions comprising the compounds and methods of use therefor.
- Who is the assignee on this patent?
- Mirati Therapeutics Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D519/00. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jun 04 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).